ROR2 and endometrial cancer: Whether the output of ROR2 signaling differs especially in colorectal and endometrial cancer, two entities substantially driven by the β-catenin-dependent, canonical WNT pathway, or whether different organ microenvironments with varying repertoires of FZDs and alternative WNT co-receptors are responsible for the diverging effects is not yet fully understood.